Abstract
In this thesis, we focus on the adaptive immune responses and new personalized treatment in sarcoidosis and pulmonary fibrosis. In part 1, we aim to identify new T cell biomarkers in sarcoidosis that may correlate with long-term prognosis or favorable response to specific treatment and unravel the role of aberrantly activated T cells in sarcoidosis pathogenesis using a novel mouse model. In part 2 of this thesis, we investigate the safety and efficacy of antifibrotic therapy in progressive pulmonary fibrosis due to asbestosis, using daily home monitoring of forced vital capacity (FVC).
| Original language | English |
|---|---|
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 5 Nov 2024 |
| Place of Publication | Rotterdam |
| Print ISBNs | 978-94-6510-134-7 |
| Publication status | Published - 5 Nov 2024 |